Big pharma

Thousands of US lawsuits claiming that the heartburn drug Zantac caused cancer have been dismissed on the basis that they are not backed by sound science.  The ruling against around 50,000 claims was made by US District Judge Robin Rosenberg in West Palm Beach, Florida. The manufacturers have repeatedly asserted that Zantac does not cause […]

The Covid-19 pandemic has given businesses opportunity to implement technology-fuelled changes to the way they operate. AI and big data/analytics have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes, as well as marketing and sales, according to a survey by GlobalData, a data and […]

Sygnature Discovery, an integrated discovery and pre-clinical solutions provider, has a new office in South San Francisco’s biotech hub at Oyster Point, where it says it can better serve current and future clients on the US west coast. The company has grown in the previous year, having recently expanded operations at its headquarters in Nottingham, […]

Udit Batra, CEO of Waters, is known as a listener, learner and gatherer of facts. He talks to Lu Rahman about Waters’ collaboration with pharma and biopharma companies to accelerate vaccine and therapy development as well as the company’s new data analysis technology. LR: We know that the last year has been all about Covid-19, […]

Andrew Aldridge, Partner at  Deepbridge Capital explains why life science sector has shot up the UK investment agenda as vaccinations are rolled out. The past twelve months have showcased the importance of medical developments like never before. Innovation in the life sciences sector has been headline news around the globe and all aspects of the healthcare system have been under the […]

Resilience in pharma and biotech supply chains is essential for the roll out of the Covid-19 vaccine, says Karl Lauri, ERP/MRP software manufacturer and distributor MRPeasy.com.  While the pandemic has highlighted the strength of the UK’s pharmaceutical and biotechnology sector, it has also shed light on the vulnerabilities of intricate, geographically extended and time-critical supply chains which needs to be prioritised. An efficient ERP/MRP ‘backbone’ will […]

by Tiago R. Felix Simply put, drugs alone are not, and will probably not be, an effective and safe treatment for most cases of nervous system disorders (NSDs). However, both society and the pharmaceutical industry seem to have so far largely overlooked the most promising alternative to drugs in the treatment of NSDs, that is, […]